to be significantly associated with gain or amplification of the epidermal growth factor receptor gene (EGFR [HGNC 3236]) on chromosome 7p12, 2 the most common genetic defect in growth factor signaling in these tumors.
This association suggests a fundamental biological role in glioblastoma pathogenesis, yet its molecular basis is poorly understood. Conceivably, the concurrent gain of EGFR and monosomy of chromosome 10 could select for a synergistic mechanism to alter EGFR transforming signaling. Such synergy could increase tumorigenic fitness and thus provide the selective pressure to conserve monosomy of chromosome 10 in glioblastomas. Based on integrative analyses of multidimensional genomic, clinical, and interactome (BOX) data and network modeling, we have pinpointed gene residents on chromosome 10 with putative reciprocal relationships to EGFR. 2 A new relationship that emerged from this analysis involves EGFR and the potential tumor suppressor gene annexin A7 (ANXA7 [HGNC 545]) 3 on 10q21.1-q21.2. ANXA7, a calciumdependent guanosine triphosphatase that binds phospholipid-containing membranes, 4, 5 has been implicated as a candidate tumor suppressor gene in breast and prostate cancer, [6] [7] [8] [9] [10] but its cancer-associated biology remains poorly understood. 11 Haploinsufficiency (Box) occurs when a diploid organism (2 copies of each chromosome), such as a human, has only 1 functional copy of a gene that does not produce enough protein to sustain a wild-type phenotype. 12 In cancer biology, a tumor suppressor gene is termed haploinsufficient if the mutation or loss of only 1 allele (Box) is sufficient to induce a cellular phenotype that leads to tumorigenesis without inactivation of the wild-type allele. 13 Haploinsufficiency of ANXA7 has been shown to be pertinent in cancer cells 11 ; reduced production of ANXA7 as a result of monosomy of chromosome 10 could thus diminish the ability of ANXA7 to function properly in glioblastomas. 2 We hypothesize that haploinsufficiency of ANXA7 provides an additional mechanism for tumorigenic increase in EGFR signaling in glioblastomas, and thus offers an explanation for the conservation of monosomy 10 in these tumors. We investigated the mechanism of deregulation of ANXA7 in glioblastomas, its link to EGFR signaling, and its association with patient outcome.
METHODS

Tumor Samples
Fifty-nine snap-frozen glioma specimens and 25 formalin-fixed paraffinembedded glioma specimens were collected at Stanford University, Palo Alto, California, and Northwestern University, Chicago, Illinois, respectively, under institutional review boardapproved guidelines and subjected to standard World Health Organization (WHO) classification.
14 Written informed consent was obtained from all patients. Specimens were analyzed by a neuropathologist to confirm the histological diagnosis and the presence of vital tumor tissue without excessive contamination (Ͻ10%) by normal brain and tumor necrosis. Genomic DNA was isolated using the DNeasy tissue kit (Qiagen, Germantown, Maryland), DpnII restriction endonuclease-digested (New England BioLabs, Beverly, Massachusetts), and purified using the QIAquick PCR purification kit (Qiagen). Genomic DNA was also extracted from a postmortem human normal brain tissue. Normal human karyotype DNA
Box. Glossary
Alleles are mutually exclusive alternative forms of the same gene occupying the same locus on homologous chromosomes, differing in DNA sequence and governing the same biochemical and developmental process. In diploid organisms with 2 copies of each chromosome, including humans, 2 alleles make up the individual's genotype. Allelic insufficiency refers to a biologically relevant alteration in gene dosage caused by the loss of a functional allele. Aneuploidy is deviation of the chromosomal constitution of cells from the normal by the addition or subtraction of chromosomes or chromosome pairs. In a normal diploid cell, the loss of a chromosome pair is termed nullisomy, the addition of a chromosome pair is tetrasomy, the loss of a single chromosome is monosomy, and the addition of a single chromosome is trisomy. Double minute chromosomes are representative small circular fragments of extrachromosomal DNA observed in many human tumors that frequently harbor amplified oncogenes and genes involved in drug resistance, therefore giving tumor cells selective advantage for growth and survival. Double minutes, like normal chromosomes, are composed of chromatin and replicate in the nucleus of the cell during cell division; but unlike typical chromosomes, they contain no centromere or telomere. Gene knockdown is any of various techniques to reduce the expression of a gene without eliminating it entirely. The reduced expression may be permanent or via a transient mechanism.
Haploinsufficiency occurs when a diploid cell only has a single functional copy of a gene that does not produce enough of a gene product (typically a protein) to permit the cell to function normally, leading to an abnormal or diseased state. Interactome is the whole set of molecular interactions in cells, most notably proteinprotein interactions and protein-DNA interactions. Monosomy is a chromosomal abnormality consisting of the absence of 1 chromosome from the normal diploid number. Raw Agilent human genome CGH microarray 244A data were background corrected using subtraction and then replacement of negative or zero values with half the minimum of the positive corrected values on the array and then locally weighted least squares (LOWESS) normalized using the "limma" package for R statistical software (R Foundation for Statistical Computing [http:/ /www.r-project.org/]). Circular binary segmentation (CBS) from the R package "snapCGH" was used to estimate segmented regions of equal dosage along each chromosome. Gene dosage segments were classified as having chromosomal gain or loss if the absolute value of the predicted dosage was more than 0.75 times the interquartile range of the difference between observed and predicted values for each region. The downloaded mRNA transcript expression data were background corrected and normalized using the robust multigene average algorithm 15 as described by TCGA. 16 For survival analysis, a unified data set of genome-scale expression data for 191 glioblastomas was retrieved from Lee et al. 17 Similarly, 2 publicly available high-grade glioma data set studies from the University of Texas M.D. Anderson Cancer Center 18 and the University of California, Los Angeles, 19 as well as a third unpublished data set from Harvard University, all profiled using the Affymetrix human genome U133A array platform, were analyzed as a unified data set.
Cell Lines and Cell Culture
Glioblastoma cell lines LN229 and U87 were obtained from the American Type Culture Collection (Manassas, Virginia) and were cultured in a humidified incubator at 37°C and 5% CO 2 with 10% fetal bovine serum and 1% penicillin/streptomycin (Invitrogen, Carlsbad, California)-supplemented Dulbecco's Modified Eagle Medium (DMEM, Mediatech Inc, Herndon, Virginia). Primary brain tumor stem cell cultures were generated from fresh glioblastoma tissue by enzymatic dissociation using collagenase and deoxyribonuclease. Tumor cells were resuspended at a density of 5ϫ 10 4 cells/mL in serum-free DMEM/F12 with N2 and B27 nutrient additives supplemented with epidermal growth factor (EGF, 20 ng/ mL), fibroblast growth factor (20 ng/ mL) (BD Biosciences, San Jose, California), and leukemia-inhibiting factor (10 ng/mL) (Millipore, Billerica, Massachusetts). Tumor spheres were usually detectable within the first week in vitro. For passaging, spheres were dissociated using Accutase (Millipore) and subcultured as previously detailed. Fetal neural stem cells were obtained and maintained as described. 20 Adult human astrocytes were harvested from temporal lobe tissue obtained during anterior temporal lobectomy with amygdalo-hippocampectomy and grown in DMEM/F12 supplemented with 10% fetal bovine serum.
Fluorescence In Situ Hybridization
Fluorescence in situ hybridization analysis for chromosomal and extrachromosomal EGFR gene dosage was performed according to previously described methods 21 using a probe targeting the EGFR locus and a probe specific for the centromeric region of chromosome 7 (Spectrum Orange dye and Spectrum Green dye, respectively, Abbott Molecular, Abbott Park, Illinois). Nuclei were counterstained with Hoechst 33342. For image acquisition and analysis, samples were visualized using an Axiovert 200 standard fluorescence microscope (Zeiss, Thornwood, New York) with a 120-W short-arc lamp, excitation and emission filters appropriate for Spectrum Orange (EGFR locus-specific signals), Spectrum Green (centromere 7-specific signals), Hoechst 33342 (nuclear) staining, and X40/ X63 objectives (Pan-Neofluar, Zeiss). Images were captured using an Axiocam HRc digital microscope camera (Zeiss), and the accompanying Axiovision 4.5 software (Zeiss).
Protein Extraction and Immunoblotting
Cell lysates from wild-type and transfected LN229 and U87 cells were prepared using the Cell Lysis Buffer (Cell Signaling Technology, Danvers, Massachusetts) containing protease and phosphatase inhibitors (Sigma-Aldrich, St Louis, Missouri), sonicated and total protein was quantitated using Pierce BCA Protein Assay Kit (Thermo Scientific, Rockford, Illinois). Blots were exposed to anti-EGFR (Assay Designs, Ann Arbor, Michigan), anti-ANXA7 (Santa Cruz Biotechnology, Santa Cruz, California), antiphospho-ERK1/2 (Thr202/Tyr204; Assay Designs), and anti-␣-tubulin (Sigma Aldrich) monoclonal antibodies recognized by an HRP-conjugated horse antimouse secondary antibody (Cell Signaling); and antiphospho-EGFR (Tyr1086; Invitrogen), anti-ERK1/2 (Abcam, Cambridge, Massachusetts), and antiphospho-AKT1/2/3 (Ser473; Santa Cruz, California) polyclonal antibodies recognized by an HRP-conjugated goat anti-rabbit secondary antibody (Cell Signaling). Enhanced chemiluminescent reagent (Bio-Rad, Hercules, California) was added to the membranes according to the manufacturer's protocol and visualized by autoradiography. Bands were quan-tified using ImageJ software version 1.42 (National Institutes of Health, Bethesda, Maryland [http://rsb.info.nih.gov/ij/]) and normalized to ␣-tubulin loading control.
In Situ Proximity Ligation Assay
We measured ANXA7 protein in tumor samples using a highly sensitive proximity ligation assay. 22, 23 For sample pretreatment, 4-µm-thick formalinfixed paraffin-embedded tumor sections or a 4-µm-thick tissue microarray were deparaffinized then epitope-retrieved in Citrate Buffer pH6.0 (DBS, Pleasanton, California) under pressure boiling for 5 minutes. After an additional 40 minutes and cooling to room temperature, slides were permeabilized with a 0.1% Triton X-100 solution and rinsed in phosphate-buffered saline. The Duolink procedure (Duolink PLA Kit; Olink, Uppsala, Sweden) was followed as directed by the manufacturer. Slides were incubated with mouse anti-Annexin A7 primary antibody (2 ng/µL; Santa Cruz Biotechnology) at 4°C. Number 1 glass coverslips (VWR International, West Chester, Pennsylvania) were mounted on samples with Vectashield Mounting Medium (Vector Laboratories, Burlingame, California).
For image acquisition and analysis, samples were visualized using an Axiovert 200 standard fluorescence microscope (Zeiss) with a 120-W short-arc lamp, excitation and emission filters appropriate for Texas Red (proximity ligation assay signals) and Hoechst 33342 (nuclear) staining, and an X40 objective (Pan-Neofluar; Zeiss). Images were obtained using an Axiocam HRc and Axiovision 4.5 software. For quantification of ANXA7 protein, images were converted to 8-bit grayscale tag image file format (TIF) images and analyzed using BlobFinder software V3.0 (Uppsala University, Uppsala, Sweden [www.cb .uu.se/~amin/BlobFinder/]) to provide the total number of proximity ligation assay (single protein) signals and the total number of nuclei using average signal count analysis (after optimization and standardization of nucleus size, blob size, blob intensity, and cytoplasm radius). Images were obtained using an LSM 510 laser scanning confocal microscope (Zeiss).
Bisulfite Treatment and Polymerase Chain Reaction
Bisulfite modification of genomic DNA was performed using the EZ DNA Methylation-Gold kit (Zymo Research, Orange, California) according to manufacturer's instructions (0.5 µg of DNA was bisulfite-treated, eluted with 20 µL elution solution, and stored at -20°C until ready for use). Nested polymerase chain reaction (PCR) reactions were adopted to amplify the ANXA7 gene promoter region. Two runs of PCR reactions were carried out using the Hotstart Taq polymerase kit (Qiagen) in 25 µL total volume and with 50 pM of forward primer and reverse primer. In the first PCR reaction, 50 ng of the bisulfite-converted DNA in 1 µL was used as a template. After 3 minutes of initial denaturation at 95°C, the cycling conditions of 25 cycles consisted of denaturation at 95°C for 15 seconds, annealing at 50°C for 15 seconds, and elongation at 72°C for 15 seconds. One microliter of PCR product from the first run was used as the template for the second PCR reaction, which after initial denaturation at 95°C for 3 minutes comprised 45 cycles with denaturation at 95°C for 15 seconds, annealing at 47°C for 15 seconds, and elongation at 72°C for 15 seconds. The primers used in the first PCR run were 5−GAG GTG GGA AAG GGA GG-3Ј and 5Ј-AAA AAT CTT TTT CCC TCA AAT AAC-3Ј; those of the second PCR run were 5Ј-AAA CTA AAA AAC AAC CC-3Ј and biotinylated primer 5Ј-/5Biosg/TTT TTT ATT TGA TTT TAG TAG TAG-3Ј. The PCR products were stored at 4°C until ready for pyrosequencing.
Pyrosequencing
Pyrosequencing, a method of DNA sequencing based on the sequencing by synthesis principle 24 that can accurately quantify methylation patterns at individual nucleotide positions, was performed as previously described 25 using the PyroMark MD pyrosequencing system (Biotage, Charlottesville, Virginia). The final PCR product was purified using streptavidin-Sepharose HP beads (GE Healthcare, Uppsala, Sweden) and processed to yield singlestranded DNA. The single-stranded DNA was prepared for pyrosequencing using the PyroMark vacuum prep tool (Biotage). The PCR product was bound onto Sepharose beads. Beads containing the immobilized PCR product were washed, denatured using a 0.2M NaOH solution, washed again, and neutralized. Pyrosequencing primer at a concentration of 0.3 µM was annealed to the purified single-stranded PCR product at 28°C. The primer sequence to determine the methylation level of 9 CpG sites within the ANXA7 promoter located close to the transcriptional start site was 5Ј-ACT AAA AAA CAA CCC-3Ј. Methylation quantification was performed using the manufacturer-provided software (Biotage) with default settings.
Retroviral Infection and EGF Stimulation
Retroviral production was performed in tsA54 packaging cells as previously described. 26, 27 Human short hairpin (sh)ANXA7 knockdown retroviral construct in a pSM2 vector (Open Biosystems, Huntsville, Alabama) targeting the 1073-1093 mRNA sequence of ANXA7 was cotransfected with pIK packaging vector. Human empty retroviral vector pBabe (EV) was used as a retroviral control. For stable ANXA7 knockdown, U87 cells were retrovirally infected for 2 days, twice a day for 4 hours, in the presence of 5 to 10 µg/mL Polybrene (Sigma-Alrich), followed by 3 days of 1 µg/mL Puromycin selection (Calbiochem, San Diego, California). Transduced cells were stably maintained in 0.5 µg/mL Puromycin selection. For transient transfection, LN229 and U87 cells were transfected with shANXA7 pSM2 and N-terminal FLAG-tagged EGFR pcDNA3.1 plasmids using Lipofectamine 2000 (Invitrogen). Transfected cell lines were selected after 2 to 3 passages over 15 days in 250 µg/mL G418 (Calbiochem) and 1 µg/mL Puromycin. For epidermal growth factor (EGF) stimulation experiments following 24 hours serum starvation, U87-ANXA7 knockdown and U87-EV cells were stimulated with 50 ng/mL recombinant human EGF (SigmaAlrich) and assayed at various time points (0-, 30-, 60-, and 90-minute) for total and phosphorylated EGFR, extracellular signal-regulated kinase 1/2 (ERK1/2), and V-akt murine thymoma viral oncogene homolog 1/2/3 (phosphorylated AKT1/2/3) abundance by immunoblotting.
Real-Time Reverse Transcription PCR
Quantitative real-time reverse transcription PCR (qRT-PCR) reactions were performed with the ABI 7900HT Fast Real-Time PCR System and Sequence Detection Software V2.3 (Applied Biosystems, Foster City, California) using prevalidated TaqMan Gene Expression Assays (Applied Biosystems) designed to amplify the EGFR mRNA transcript and the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) housekeeping mRNA transcript. Total RNA (5 µg) from U87-EV, LN229-EV, U87-shANXA7, and LN229-shANXA7 cells was extracted using the RNeasy Mini Kit (Qiagen) and reverse transcribed using the SuperScript III first-strand synthesis system for RT-PCR (Invitrogen). Thermocycling for each PCR reaction was carried out in a final volume of 20 µL containing 100 ng of complementary DNA, 1 TaqMan MGB probe (6-FAM dyelabeled), 250 nM final concentration, and 1X TaqMan Universal PCR Master Mix. After 10 minutes of initial denaturation at 95°C, the cycling conditions of 40 cycles consisted of denaturation at 95°C for 15 seconds followed by annealing and extension at 60°C for 1 minute. All reactions were performed in triplicate. Relative quantitation studies were carried out in RQ Manager Software version 1.2 (Applied Biosystems) using the ⌬⌬ threshold cycle (C T ) method.
Soft-Agar Assay
Retrovirally transfected/transduced LN229 and U87 cells were trypsinized, counted, and suspended in 0.2% agar in 20% fetal bovine serum DMEM, and plated in duplicate on 60-mm dishes containing 0.5% agarose at 1ϫ10 5 cells per plate. DMEM medium was changed every alternate day. Colonies were observed and counted at 3 different sites at various time points (day 15 to 35), stained for viability with 3 mg/mL 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) dye (Calbiochem) for 4 hours, and visualized with a standard light microscope. Colony formation indicates that individual cells develop into cell clones that are identified as single colonies. Colony formation or colony-forming activity is a phenotypically recognizable characteristic of cell transformation and a measure of malignant tumor cell behavior.
Mutational Analysis
Sequencing data and inferred mutations generated at the Broad Institute, Cambridge, Massachusetts were obtained from TCGA. At the time of this report, mutations were reported for 149 unique tumor samples. In this project, the Sanger/di-deoxy method was used to sequence whole genome-amplifiedgenomic DNA from tumor and paired normal samples. After correcting for the background nucleotide-specific mutation rate and sequence coverage of each gene, mutations were called (ie, identified as missense mutations, frameshift mutations, etc) and then verified by comparison with DNA sequence derived from normal tissue from the same patient using a second genotyping platform. Furthermore, a recent genomewide mutational study of glioblastoma 28 was queried for reported ANXA7 mutations, which has sequenced the protein coding exons of 23 219 mRNA transcripts representing 20 661 genes in 22 glioblastoma samples using nextgeneration sequencing technology.
Statistics and Survival Analysis
All statistical calculations were performed using R version 2.8.1 and packages from the Bioconductor release 2.3 (Bioconductor, http://www .bioconductor.org/). Unless otherwise stated, statistical significance was established according to 2-sided P values of less than .05 for all statistical tests.
Linear regression analysis was used to assess the relationship between gene dosage and mRNA transcript expression for ANXA7 in the TCGA set and for the promoter methylation/mRNA expression and gene dosage/mRNA expression relationships in the Stanford set, using mRNA transcript expression as the outcome and gene dosage or promoter methylation as the predictor. Scatterplots and LOWESS smooths were used to confirm the suitability of linear regression analyses, and statistical significance of these relationships was assessed according to the P value for the estimated slope of the regression line. The unpaired t test and Wilcoxon rank-sum test were used as appropriate.
Survival curves between groups were estimated by the Kaplan-Meier productlimit method and survival distributions between groups were compared using the Mantel-Cox log-rank test. Univariate and multivariate Cox proportional hazards regression analyses were performed with overall duration of survival as the dependent variable and gene dosage or mRNA transcript expression as the primary predictor of interest. The assumption of proportional hazards was tested using interactions of the predictor variables with time. The circular binary segmentation and robust multigene average preprocessing algorithms yield continuous gene dosage and expression estimates on a log 2 scale of red (Cy5 dye) and green (Cy3 dye) fluorescence intensities (specifically ratios of Cy5 to Cy3 dyes or log 2 R/G), thereby rendering the interpretation of the hazard ratios (HRs) in the Cox models with continuous versions of these predictors somewhat difficult. For easier HR interpretation, we dichotomized mRNA transcript expression at the median and used circular binary segmentation-derived gene dosage loss/wild-type information as binary predictors in the Cox models with overall survival as the outcome. Our characterization of a nonrandom genetic landscape in human gliomas highlighted a significant association between chromosomal alterations containing the EGFR and ANXA7 genes. 2 A specific comparison of gene dosage data from TCGA for these 2 genes confirmed a significantly decreased ANXA7 gene dosage for EGFR amplified (n=69; median ANXA7 log 2 R/G = −0.550) vs EGFR-wild-type tumors (n=124; med i a n A N X A 7 l o g 2 R / G = − 0 . 3 0 5 ) (P =1ϫ 10 −9 ; Wilcoxon rank-sum test; FIGURE 1). These analyses included 193 samples for which all EGFR probes on the Agilent aCGH array yielded consistent amplification or wild-type calls. Additional probe-specific analyses using all 219 samples demonstrated similar results.
RESULTS
Patients
Fifty-nine patients treated at Stanford University between April 5, 2001, and April 19, 2004, constituted the initial molecular discovery set. Diagnoses included 36 glioblastomas, 8 astrocytic tumors
ANXA7 Gene-mRNA Transcript and Gene-Protein Relationships
Previous analyses of TCGA pilot project data 2 also identified a significant gene dosage-to-expression relationship for ANXA7. Linear regression of ANXA7 mRNA transcript expression on ANXA7 gene dosage in TCGA confirms a significant gene dosage effect on transcrip- tion for ANXA7 (P = 1 ϫ 10 −15 ; 174 samples with 1 outlier excluded; FIGURE 2). We further compared ANXA7 protein abundance in glioblastomas with heterozygous ANXA7 loss (of 1 allele) to that in glioblastomas with wild-type ANXA7 status in a panel of 12 tumors (6 vs 6) from Stanford University. Proximity ligation assay analysis disclosed significantly less ANXA7 protein abundance in tumors with monoallelic ANXA7 loss than in wildtype tumors (P=.004; unpaired t test; FIGURE 3A). Although none of the ANXA7-deleted tumors had a complete loss of ANXA7 protein expression (indicating a complete gene loss), they showed on average (SEM) a 91.5% (2.3%) reduction of expression compared with the median expression of wild-type tumors ( Figure 3B ). We extended the ANXA7 proximity ligation assay analysis to a panel of 25 high-grade gliomas from Northwestern University. We were able to analyze ANXA7 protein expression in all but 1 sample (n = 24) that was excluded from the analysis due to red blood cells masking the tumor burden. These 24 tumors showed a spread (range percentage of population median, 6.3-1459.2) of ANXA7 protein expression similar to that of the Stanford set (range, 10.9-1372.8), with a portion of tumors showing very low expression ( Figure 3A ).
Epigenetic Regulation of ANXA7
Epigenetic mechanisms-especially differential gene promoter methylationcould also affect the expression of ANXA7 in gliomas. Analysis of the methylation status of 9 CpG sites in the ANXA7 promoter of 59 human glioma samples from patients treated at Stanford University revealed no substantial difference in ANXA7 promoter methylation patterns between various glioma subtypes and both glioma tissue and reference tissues, including normal human karyotype, normal human brain, normal adult astrocytes, and fetal neural and glioblastoma-derived stem cells (FIGURE 4A and eFigure available at http://www.jama.com). Linear regression of ANXA7 mRNA transcript expression on ANXA7 promoter methylation (average profile of 9 CpG sites) in 45 Stanford University tumors with combined expression and methylation profiles revealed no significant association (P = .627; Figure 4B ). By contrast, linear regression of ANXA7 mRNA transcript expression on ANXA7 gene dosage in the same tumors disclosed a significant gene dosage effect on transcription for ANXA7 (P=.0005; Figure 4C ). We found no difference in ANXA7 promoter methylation between ANXA7-deleted tumors (2.07 [mean % SD, 0.81]) vs nondeleted tumors (1.98 [mean % SD, 0.58]); P = .707 by unpaired t test.
ANXA7 Loss Augments EGFR and EGFR Signaling
We mimicked a heterozygous gene loss by silencing the ANXA7 gene in LN229 and U87 glioblastoma cells via retroviral transfection of shRNAs targeting ANXA7 mRNA. We found that gene knockdown (Box) of ANXA7 markedly increased EGFR protein abundance (FIGURE 5A). We found mean (SEM) 744% (34.0%) and 72% (9.3%) increases in total EGFR protein in ANXA7 knockdown LN229 and U87 cells, respectively, compared with corresponding control cells transfected with empty vector only. Furthermore, the knockdown of ANXA7 was associated with increased EGFR activation, resulting in activation of the RASmitogen-activated protein kinase and the phosphatidylinositol 3-kinase (PI3K)-AKT pathways, as evidenced by sustained phosphorylation of EGFR at its autophosphorylation site (Tyr1086) and augmented ERK1/2 (at Thr202/ Tyr204) and AKT (at Ser473) phosphorylation ( Figure 5B ). We also studied the effect of ANXA7 knockdown on EGFR mRNA transcript expression in LN229 and U87 cells. We found that ANXA7 knockdown reproducibly resulted in a moderate (mean [SEM], 19.2% [3.1%] and 18.4% [1.5%] for LN229 and U87 cells, respectively) although significant (LN229 and U87, P = .0015 and P = .0002, respectively; unpaired t test) increase in EGFR mRNA transcript expression in both cell lines (FIGURE 6). This finding is consistent with previous reports suggesting a positive feed-forward circuit of EGFR selfpromoted expression in which EGFR activation induces a signaling cascade that increases the expression and stability of its own mRNA transcript. [29] [30] [31] We further studied the effect of ANXA7 knockdown on the prevalence of EGFR gene dosage located on small fragments of extrachromosomal DNA-socalled double minute chromosomes (Box)-described for EGFR in glioblastomas. 32 We found no evidence of increased EGFR gene dosage at its normal chromosomal 7p12 locus or extrachromosomal EGFR gene dosage in ANXA7 knockdown cells: LN229-EV as well as LN229-shANXA7 were tetraploid (4 copies) both for EGFR and chromosome 7, and U87-EV as well as U87-shANXA7 were diploid both for EGFR and chromosome 7 (FIGURE 7).
ANXA7 Haploinsufficiency Promotes Glioblastoma Cell Tumorigenicity
Because of its profound effect on EGFR signaling, we assessed whether loss of ANXA7 function might affect the biological behavior of glioblastoma cells. We found that knockdown of ANXA7 in U87 glioblastoma cells via transfection of ANXA7-targeting shRNA mimicked the loss of 1 allele (50% ANXA7 protein abundance compared with control cells) and thus an ANXA7 haploinsufficient state ( Figure 5A) , and resulted in a mean (SEM) 49% (9.8%) increase in colony-forming activity in soft agar (P=.033; unpaired t test) relative to that in cells transfected with control vector only. Pronounced knockdown of ANXA7 (protein levels 20%-25% of control cells) in LN229 and U87 cells led to an even more prominent 
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EGFR (epidermal growth factor receptor) mRNA transcript expression based on quantitative real-time polymerase chain reaction in LN229-EV vs LN229-shANXA7 cells (P = .0015) and in U87-EV vs U87-shANXA7 cells (P = .0002). ANXA7 knockdown results in a moderate though significant increase in EGFR mRNA transcript expression in both cell lines. Error bars denote standard error of the mean. P values according to unpaired t test. effect on colony-forming activity compared with that in LN229 and U87 control cells (LN229, P = .0009; U87, P =.0003; unpaired t test), with mean (SEM) increases in colony-forming activity of 215% (20%) and 203% (23%), respectively (FIGURE 8).
Tumorigenic Synergism Between ANXA7 and EGFR
To assess whether there is a cooperative effect on gliomagenesis of combined loss of ANXA7 and gain of EGFR, we compared the tumorigenic potential of glioblastoma cells engineered to express empty control vector, ANXA7 mRNA-targeting shRNA, EGFR, or ANXA7 mRNA-targeting shRNA and EGFR combined in LN229 and U87 cells. Isolated knockdown of ANXA7 again substantially increased the colony-forming activity of glioblastoma cells. EGFR overexpression alone resulted in increased colony sizes but had only a moderate effect on colony numbers. Combined ANXA7 silencing and EGFR overexpression reproducibly amplified the tumor-promoting effect of isolated ANXA7 knockdown in LN229 and U87 cells (P = .0002 and P =.001, respectively; unpaired t test), resulting in mean (SEM) 204% (12%) and 206% (18%) increases in colonyforming activity (Figure 8 ). These data suggest a tumorigenic synergism between ANXA7 loss and EGFR amplification.
ANXA7 Is a Putative Haploinsufficiency Gene in Glioblastomas
We analyzed the sequencing data for ANXA7 generated by phase I highthroughput sequencing in TCGA to test whether ANXA7 might be a haploinsufficiency gene in glioblastomas. Out of 15 067 identified mutations across 410 genes in 149 unique TCGA glioblastoma samples, only 11 matched to ANXA7 involving 9 samples (Ϸ6% of all analyzed samples), 4 of which were validated using a second technology. Mutations included 7 missense mutations and 4 frame-shift deletions. A correlation of these mutations with ANXA7 gene dosage status reveals that all tumors (except 1 without dosage data in TCGA) also had ANXA7 deletions. We further queried a recent genome-wide mutational study of 22 glioblastomas, which has sequenced the proteincoding exons of 23 219 mRNA transcripts representing 20 661 genes including exons 1 through 7 and 9 through 12 of ANXA7. 28 This study has revealed no somatic mutations in ANXA7 in glioblastomas.These data indicate that small-scale mutations of ANXA7 are rarely present in glioblastomas. Since the frequent (Ϸ75%) deletion of the ANXA7 locus in glioblastomas usually involves the loss of only 1 allele, ANXA7 may indeed function as a haploinsufficiency gene in these tumors.
ANXA7 mRNA Transcript Expression Associated With Malignant Glioma Outcome
To evaluate the effect of ANXA7 haploinsufficiency on patient outcome, we assessed the association of ANXA7 mRNA transcript expression with the duration of overall survival. In a cohort of 191 glioblastomas, 17 ANXA7 mRNA transcript expression was associated with duration of overall survival (HR, 0.74; 95% confidence interval [CI], 0.58-0.95; P=.019; Cox proportional hazards regression), such that loss of expression of ANXA7 denoted a proportionally unfavorable prognosis. A multivariate Cox model incorporating the established prognostic covariates of patient age, disease status (primary vs recurrent), and O 6 -methylguanine-DNA methyltransferase-currently the most established molecular marker predicting response to standard-of-care treatment in glioblastomas 33 -sustained an independent association between duration of patient survival and ANXA7 mRNA transcript expression (HR, 0.74; 95% CI, 0.57-0.95; P=.019).
A 2-class model stratifying patients according to median ANXA7 mRNA transcript expression also demonstrated significance for ANXA7 (P=.008; log-rank test; HR, 0.667; 95% CI, 0.493-0.902), with median durations of survival of 70 vs 51 weeks and 46.9 vs 74.8 deaths per 100 personyears for high vs low ANXA7 expression, respectively (FIGURE 9A). Median duration of follow-up was 70 weeks (1.4, 479) and a 2-class model based on deletion status (log-rank P = .106) failed to display a significant association between duration of survival and PTEN gene dosage. Finally, we compared a 2-class model that incorporates deletion information for both genes with the 2-class model based only on ANXA7 deletion status. We included in this model only those 177 tumors that either showed deletions of both ANXA7 and PTEN (n = 144) or showed wild-type status for both genes (n = 33). As opposed to the ANXA7 single-gene model, we did not find a significant difference in duration of survival between patients with ANXA7/ PTEN codeleted tumors and those with ANXA7/PTEN wild-type tumors (logrank P = .065). These analyses establish that an effect on ANXA7 gene dosage underlies the clinical relevance of loss of genetic material on chromosome 10q.
COMMENT
The dismal prognosis in glioblastoma outcome, even with the most advanced clinical care, addresses the need for the translation of new biological insights into clinical end points that can ultimately influence patient management. Identification of genes in which expression is altered or pathways in which activity is modified in tumors is important to understanding basic tumor biology, developing clinical-pathological correlations, and identifying points of therapeutic intervention. As we demonstrate here for ANXA7 and its link to EGFR signaling and dysregulation in glioblastomas, these require integration of genomic analysis, cancer genetics and biology, and clinical validation. 
LN229 U87
Significantly increased colony-forming activity of shANXA7 cells compared with EV cells (EV is reference) (LN229-shANXA7 vs LN229-EV: P=.0009; U87-shANXA7 vs U87-EV: P = .0003) and of shANXA7/ EGFRϩ cells compared with shANXA7 cells (LN229-shANXA7/EGFRϩ vs LN229-shANXA7: P = .0002; U87-shANXA7/EGFRϩ vs U87-shANXA7: P=.001).
Error bars denote standard error of the mean colony number of multiple experiments (colony-forming activity also assessed in EV cells). P values according to unpaired t test. ANXA7 indicates annexin A7; EGFR, epidermal growth factor receptor.
Dysregulation of EGFR signaling has been associated with a number of human cancers and represents the target of an expanding class of anticancer therapies. Gains and activating mutations of EGFR occur in about 45% of glioblastomas 16 and are invariably associated with EGFR overexpression. About two-thirds of these tumors show overexpression of the corresponding protein, suggesting that additional mechanisms of EGFR deregulation exist.
Our integrated ANXA7 gene dosage and sequence analysis in TCGA and our functional data suggest that ANXA7 functions as a haploinsufficiency gene in glioblastomas. Although TCGA data indicate that glioblastomas harbor heterozygous (mono-allelic) ANXA7 losses and still express, yet at significantly diminished levels, the ANXA7 mRNA transcript from the retained allele, we found a seemingly low ANXA7 protein abundance in ANXA7-deleted tumors compared with that of wild-type tumors. This observation is consistent Log-rank P = .008
Log-rank P = .04 Log-rank P = .03
Log-rank P <.001 
